Regenxbio
RGNX
184 hedge funds and large institutions have $1.12B invested in Regenxbio in 2021 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 92 increasing their positions, 34 reducing their positions, and 28 closing their positions.
171% more repeat investments, than reductions
Existing positions increased: 92 | Existing positions reduced: 34
4.23% more ownership
Funds ownership: 73.08% → 77.3% (+4.2%)
8% more call options, than puts
Call options by funds: $3.51M | Put options by funds: $3.25M
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
4% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 28
2% less funds holding
Funds holding: 187 → 184 (-3)
10% less capital invested
Capital invested by funds: $1.24B → $1.12B (-$119M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$38.4M |
| 2 |
BlackRock
New York
|
+$37.1M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$33M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$25.6M |
| 5 |
State Street
Boston,
Massachusetts
|
+$20.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$15.7M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$4.67M |
| 3 |
Jane Street
New York
|
-$3.15M |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
-$2.28M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$2.19M |
RGNX Hedge Fund Activity: Q1 2021 in Review
184 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Regenxbio (RGNX) for Q1 2021, worth a combined $1.12B — down 9.6% from $1.24B a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of RGNX and 27 opened new positions — a net loss of 1 holder — while 34 trimmed existing stakes and 92 added.
The largest buyer was JP Morgan Chase, adding an estimated $38.4M. The largest seller was Goldman Sachs, cutting an estimated $15.7M.
- 184 institutional investors held Regenxbio (RGNX) as of Q1 2021, down from 187 in Q4 2020.
- Funds reported $1.12B of Regenxbio stock for Q1 2021, down 9.6% quarter-over-quarter.
- 27 funds opened new Regenxbio positions in Q1 2021 and 28 closed out, a net change of -1 holder.
- The largest Regenxbio buyer in Q1 2021 was JP Morgan Chase, an estimated $38.4M added.
- The largest Regenxbio seller in Q1 2021 was Goldman Sachs, an estimated $15.7M sold.
Based on aggregated 13F filings for Q1 2021.